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Urinary neutrophil gelatinase-associated lipocalin (uNGAL) has been suggested as potential early marker of delayed graft function
(DGF) following kidney transplantation (KTx). We conducted a prospective study in 40 consecutive KTx recipients to evaluate
serial changes of uNGALwithin the first week after KTx and assess its performance in predicting DGF (dialysis requirement during
initial posttransplant week) and graft function throughout first year. Urine samples were collected on post-KTx days 0, 1, 2, 4, and
7. Linear mixed and multivariable regression models, receiver-operating characteristic (ROC), and areas under ROC curves were
used. At all-time points, mean uNGAL levels were significantly higher in patients developing DGF (𝑛 = 18). Shortly after KTx
(3–6 h), uNGAL values were higher in DGF recipients (on average +242 ng/mL, considering mean dialysis time of 4.1 years) and
rose further in following days, contrasting with prompt function recipients. Day-1 uNGAL levels accurately predicted DGF (AUC-
ROC = 0.93), with a performance higher than serum creatinine (AUC-ROC = 0.76), and similar to cystatin C (AUC-ROC = 0.95).
Multivariable analyses revealed that uNGAL levels at days 4 and 7 were strongly associated with one-year serum creatinine. Urinary
NGAL is an early marker of graft injury and is independently associated with dialysis requirement within one week after KTx and
one-year graft function.
1. Introduction
Delayed graft function (DGF) is an important complication
of kidney transplantation (KTx) that adversely affects allo-
graft survival. Despite substantial improvements in the field
of KTx, the incidence of DGF is rising with the growing
practice of accepting expanded criteria donors to increase
transplantation rates [1–6]. Delayed graft function predis-
poses kidney graft to acute and chronic rejection, contributes
to progressive allograft dysfunction, and increases the risk of
premature graft loss [7–11].
Reliable biomarkers enabling early discrimination of
DGF in KTx are lacking, which impairs timely therapeutic
interventions. Traditionally, acute graft dysfunction is diag-
nosed by measuring serum creatinine, but this parameter
is an unreliable indicator of kidney function during an
episode of acute injury [12]. One of the most promising
biomarkers of acute kidney injury is neutrophil gelatinase-
associated lipocalin (NGAL), which is released to blood
from activated neutrophils during inflammatory processes.
In steady situations, this lipocalin is found in urine only in
trace. Massive NGAL quantities excreted in urine (uNGAL)
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usually indicate damage of proximal tubular cells [13–15].
Graft injury due to ischemia-reperfusion is an inevitable
consequence of KTx procedure and can result in varying
degrees of early graft dysfunction, which can be considered
a form of posttransplantation acute kidney injury. For this
reason, several studies investigated the utility of NGAL for
the diagnostic and prognostic of acute graft dysfunction
following KTx [16–27]. Recently, the prognostic value of
uNGAL on graft function at one-year after transplantation
was also examined and presented conflicting findings [22,
28].
In order to support the usefulness of uNGAL as a reliable
marker of graft injury and to clarify the role of this promising
biomarker in the prediction of kidney function beyond the
first week after transplant, we conducted a prospective study
to
(a) evaluate longitudinal changes of uNGAL levels over
the first week after KTx and identify factors associated
with these changes;
(b) assess the performance of uNGAL in predicting DGF
(defined as the requirement for dialysiswithin the first
7 days after transplantation);
(c) appraise the long-term prognostic value of uNGAL
measured within one week posttransplantation on
kidney allograft function, evaluated by one-year
serum creatinine.
2. Subjects and Methods
Consecutive patients with end-stage renal disease, undergo-
ing living or deceased KTx at Centro Hospitalar do Porto,
fromDecember 2010 toMay 2011 were prospectively enrolled.
Recruitment excluded patients less than 18 years old and
those who required a combined pancreas or liver KTx. After
transplant, patients with primary graft failure related to
surgical causes were excluded. This study was approved by
Institutional Review Board of Centro Hospitalar do Porto.
Each participant provided written informed consent before
enrolment.
2.1. Sample Collection and Measurements. Urine samples for
NGAL determination were collected 3 to 6 h after surgery
(uNGAL0 or baseline); on the following morning, nearly
8 to 12 h after graft reperfusion (uNGAL1 or first day);
and then at second (uNGAL2), fourth (uNGAL4), and
seventh days (uNGAL7), for a total of five samples for each
patient. The same laboratory technician, who was blinded to
patient information, performed uNGALmeasurements using
a two-step chemiluminescent microparticle immunoassay
on a standardized clinical platform (ARCHITECT, Abbott
Diagnostics).
Serum creatinine levels were determined preoperatively,
daily until hospital discharge, and at 1, 3, 6, and 12months
after transplantation to evaluate later graft function. Serum
creatinine measurements were performed by Jaffe´ method
(RocheDiagnostics). Cystatin Cwasmeasuredwith a particle
enhanced immunonephelometric method (Siemens Diag-
nostics) at the same time points as uNGAL, except for
baseline.
2.2. Definitions. Delayed graft function was defined, accord-
ing to United Network for Organ Sharing, as the requirement
for dialysis within the first seven days after KTx, due to
an absence or irrelevant improvement in graft function.
Complementarily, graft function was considered “prompt”
(non-DGF) if no dialysis was required during the first week
after transplantation.
Acute Rejection was defined as either biopsy-proven
rejection or antirejection treatment without biopsy.
Estimated Glomerular Filtration Rate (eGFR) was calcu-
lated using theRule’s refittedMDRD formula [29], considered
to have an improved diagnostic performance and better
accuracy of the true GFR in KTx recipients [30].
Creatinine Reduction Rate (%) was calculated as the
difference between serum creatinine at day 2 (or day 4) and
day 1, divided by serum creatinine at day 1, multiplied by 100.
Graft function at one year was evaluated by the average
of the two serum creatinine levels measured closer to one
year after KTx (e.g., by the average values seen at 12 and
13months). It was thought that this would reflect more
accurately the usual graft function, since a single measure
could bemore easily inflated by acute situations, like a urinary
infection for example. Two grafts were lost at seventh and
eighth months and the last serum creatinine presented by
these patients prior to dialysis restart was considered as being
the one-year creatinine.
2.3. Statistics. Kolmogorov-Smirnov test was performed to
assess deviation from normal distribution. Quantitative vari-
ables were summarized asmean and standard deviation (SD),
or asmedian and 25th–75th quartiles (interquartile range) for
variableswith skewed distribution. Categorical variableswere
reported as percentages.
Statistical analysis was performed in five steps. Firstly,
a cross-sectional bivariate analysis was done to compare
groups and study the association between uNGAL and
demographic/clinical variables. Continuous variables were
compared using either parametric (t-test) or nonparamet-
ric (Mann-Whitney) tests. Associations between categorical
variables were analyzed using the 𝜒2 test and Fisher’s exact
test as appropriate. Correlations between uNGAL and con-
tinuous variables were assessed using Pearson correlation
and uNGAL levels were log-transformed (ln) before analysis.
Spearman correlationwas used to analyze uNGAL and serum
creatinine reduction ratio on posttransplant days 2 and 4.
Secondly, we used a longitudinal analysis to study uNGAL
kinetics and modelling it as a response variable on time. A
linear mixed-effects model was used to study the association
of DGF with serial changes of uNGAL (log-transformed),
controlling for donor status (living/deceased), recipient’s age,
time on dialysis, and time measurement of uNGAL. The
interaction between DGF and uNGAL time measurement
was included in the model, as such a significant interaction
would suggest that DGF affects the uNGAL levels trajectory.
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Thirdly, receiver-operating characteristics analysis was
performed to estimate the sensitivity and specificity of
uNGAL (as well as serum creatinine and cystatin C) to
predict DGF. The optimal cut-off points were determined by
maximizing the sum of sensitivity and specificity.
Fourthly, multivariable logistic regression analysis was
undertaken to evaluate whether uNGAL levels were indepen-
dently associated with DGF. Pretransplant variables known
to be associated with DGF and considered potential con-
founders were included in the models. To avoid collinearity
each time point uNGAL was included separately in different
models. The final models were fitted using a backward
selection procedure.
Fifthly, multivariable linear regression was used to
describe the independent association of uNGAL with renal
function at 12months evaluated by serumcreatinine, adjusted
for the variables that usually predict graft function, including
donor status, rehospitalizations, and acute rejection episodes
throughout the first year. Linear regression models used
log-transformed uNGAL and serum creatinine levels. As in
logistic models, uNGAL at each time point were included
separately in models to avoid collinearity.
All statistical analyses were done with SPSS version 20.0
and a significance level of 0.05 was considered.
3. Results
During time recruitment, 42 patients were enrolled. Two
recipients had renal artery thrombosis and were excluded in
the first two posttransplantation days. Therefore our study
sample included 40 recipients. Baseline data are shown in
Table 1.
3.1. Urinary NGAL. The first urine sample (uNGAL0) was
obtained from 30 patients. On the following days, urine
samples were collected from 35 patients at the first, second,
and seventh days, and from 36 patients at the fourth day.
All of our subjects provided at least two urine samples.
Only, one patient provided merely two urine samples and the
remaining 39 subjects provided 3 ormore urine samples (with
20 patients providing all five samples).
Daily median uNGAL levels did not differ significantly
between male and female recipients, except for the seventh
day where female uNGAL levels were significantly higher.
Concerning donor status, uNGAL levels were higher in
deceased donor recipients at all-time points, but only sta-
tistically significant at second day. Except for the seventh
day, uNGAL levelswere significantly andpositively correlated
with cold ischemia time (𝑟 = 0.45, 𝑃 = 0.02; 𝑟 = 0.36,
𝑃 = 0.04; 𝑟 = 0.56, 𝑃 = 0.001; 𝑟 = 0.46, 𝑃 = 0.006, resp.,
at baseline, first, second, and fourth days).
At most time points, uNGAL was positively and signif-
icantly correlated with recipient age (𝑟 = 0.39, 𝑃 = 0.02;
𝑟 = 0.39, 𝑃 = 0.02; 𝑟 = 0.44, 𝑃 = 0.007; resp., at first, second,
and seventh days) and pretransplant dialysis time (𝑟 = 0.48,
𝑃 = 0.008; 𝑟 = 0.37, 𝑃 = 0.03; 𝑟 = 0.43, 𝑃 = 0.01; 𝑟 = 0.33,
𝑃 = 0.024; resp., at baseline, first, second, and seventh days).
No significant correlation was found with HLA mismatches
and with donor age and serum creatinine.
Urinary NGAL levels were significantly and positively
correlated with serum creatinine at all-time points (data not
shown). Furthermore, except for uNGAL0, all the remaining
uNGAL levels were significantly and negatively correlated
with changes in serum creatinine between the second and
first days, and also between the fourth and the first days: lower
uNGAL values were associated with higher reductions rates
in serum creatinine (data not shown).
Median length of hospitalization after transplantationwas
12 days (IQR: 7–22) and uNGAL levels were highly correlated
with length of hospital stay at all-time points (𝑟 = 0.48, 𝑃 =
0.002; 𝑟 = 0.64, 𝑃 < 0.001; 𝑟 = 0.79, 𝑃 < 0.001; 𝑟 = 0.77,
𝑃 < 0.001; 𝑟 = 0.82,𝑃 < 0.001, resp., at baseline, first, second,
fourth, and seventh days).
3.2. DGF and uNGAL Longitudinal Changes. Eighteen recip-
ients (45%) had DGF, three of these were from living donors,
and 22 (55%) had prompt graft function. Concerning tradi-
tional predictors of DGF and except for cold ischemia time,
no significant differences were found between DGF/non-
DGF in relation to baseline characteristics and induction
therapy (Table 1). Mean age was significantly higher in
patients with DGF (56 (11) versus 43 (16) years in non-DGF
recipients, 𝑃 = 0.006). As expected, patients with DGF had
higher serum creatinine levels (Table 2) and lower creatinine
reduction ratios on posttransplant days 2 and 4.
Similar to serum creatinine, median uNGAL concen-
trations were consistently higher in DGF group compared
with non-DGF group at all measured time points (Table 2
and Figure 1). In patients with prompt graft function, the
longitudinal changes of uNGAL were characterized by an
initial phase with a rapid decline and then a phase with a
slower decrease continuing throughout the posttransplant
week.This pattern of changes was different inDGF recipients:
uNGAL levels increased frombaseline to the followingmorn-
ing after transplantation and remained elevated throughout
most of the follow-up period.
A linear mixed-effects model was used to study the
association of DGF with longitudinal changes of uNGAL,
controlling for variables found to be associated with uNGAL
by bivariate analysis. Pretransplant time on dialysis, time
measurement of uNGAL, and DGF were independently
associated with uNGAL levels. Adjusting for the remaining
variables, donor status and recipient age lost their statistical
significance andwere removed from the finalmodel (Table 3).
Delayed graft function was significantly associated with
uNGAL levels, with prompt function recipients having on
average lower levels of uNGAL at all-time points. According
to our estimation, for a patient with dialysis time of approx-
imately 4.1 years, the initial values of uNGAL (3–6 h after
transplantation) are about 242 ng/mL higher in patients who
went on to develop DGF, and these values will rise even
more in the following days. A significant interaction between
time of measurement and DGF confirmed that longitudinal
changes of uNGAL levels depend on whether the recipient
had DGF or not. To clarify the meaning of this interaction,
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Table 1: Summary of baseline and clinical characteristics in kidney transplant donors and recipients (total sample and categorized by delayed
or prompt graft function).
Total (𝑛 = 40) DGF (𝑛 = 18) Non-DGF (𝑛 = 22) 𝑃 value
Donor
Age (yr) 51.2 ± 11.4 51.1 ± 13.4 51.2 ± 9.9 0.172
Male gender 26 (65) 14 (78) 12 (54.5) 0.125
Living donor 11 (27.5) 3 (16.7) 8 (36.4) 0.165
Expanded criteria donors 3 (7.5) 1 (5.6) 2 (9.1) 0.541
Serum creatinine (mg/dL) 0.81 ± 0.18 0.85 ± 0.21 0.78 ± 0.16 0.318
Donor-recipient
HLA mismatches 3.39 ± 1.24 3.38 ± 1.07 3.41 ± 1.46 0.941
Cold ischemia time (h) 12.1 ± 7.9 15.2 ± 7.8 9.6 ± 7.3 0.035∗
Living donor 2.8 ± 0.5 2.5 ± 0.5 3.0 ± 0.5 0.204
Deceased donor 16.2 ± 5.9 18.1 ± 5.1 14.1 ± 6.2 0.088
Recipient
Age (yr) 49.2 ± 15.2 56.3 ± 10.9 43.3 ± 15.9 0.006∗
Male gender 26 (65) 11 (61) 15 (68) 0.641
Caucasian 40 (100) 18 (100) 22 (100) —
BMI (Kg/m2) 24.8 ± 4.9 26.2 ± 4.4 23.6 ± 5.0 0.091
Previous transplant 2 (5) 0 (0) 2 (9.1)
Time on dialysis (yr) 4.4 ± 4.7 5.6 ± 6.2 3.4 ± 2.3 0.135
Pretransplant therapy
Dialysis 38 (95) 18 (100) 20 (90.9) 0.296
Preemptive transplantation 2 (5) 0 (0) 2 (9.1)
Cause of kidney disease
IgA nephropathy 7 (17.5) 2 (11.1) 5 (22.7) —
Glomerulonephritis 6 (15.0) 4 (22.2) 2 (9.1) —
Diabetic nephropathy 5 (12.5) 3 (16.7) 2 (9.1) —
Autosomal dominant polycystic kidney disease 3 (7.5) 3 (16.7) 0 (0) —
Unknown 4 (10.0) 1 (5.6) 3 (13.6) —
Others 15 (37.5) 5 (27.8) 10 (45.5) —
Peak PRA (%) 5.5 ± 15.1 5.0 ± 15.0 5.9 ± 15.5 0.853
0 29 (72.5) 14 (77.8) 15 (68.2) —
1–25 8 (20.0) 3 (16.7) 5 (22.7) —
26–75 3 (7.5) 1 (5.6) 2 (9.0) —
Current PRA (%) 2.3 ± 8.6 3.1 ± 11.7 1.6 ± 4.9 0.585
0 34 (85) 15 (83.3) 19 (86.4) —
1–25 5 (12.5) 2 (11.1) 3 (13.6) —
26–50 1 (2.5) 1 (5.6) 0 (0) —
Induction regimen
Antithymocyte globulin (ATG-F) 4 (10) 1 (5.6) 3 (13.6) 0.613
Basiliximab/daclizumab 30 (75) 14 (77.8) 16 (72.7) 0.789
Immunosuppression at time of discharge
Steroids 38 (95.0) 18 (100) 20 (90.9) 0.296
Tacrolimus 38 (95.0) 17 (94.4) 21 (95.5) 0.886
Cyclosporine A 2 (0.05) 1 (5.6) 1 (5.6) 0.884
Values are expressed as mean ± standard deviation or absolute numbers and percentages. Comparisons between continuous variables were done using
parametric (𝑡-test) or nonparametric (Mann-Whitney) tests; associations between categorical variables were analyzed using the 𝜒2 test and Fisher’s exact test
as appropriate; ∗𝑃 < 0.05.
Abbreviations: HLA: human leukocyte antigen; BMI: body mass index; PRA: panel reactive antibody.
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Table 2: Serial levels of serum creatinine and uNGAL through the first posttransplant week, according to graft function (delayed or prompt).
Serum Creatinine
(mg/dL)
Median, (IQR)
Prior transplantation 1st day
∗
(𝑛 = 40, 18 DGF)
2nd day
(𝑛 = 40, 18 DGF)
4th day
(𝑛 = 40, 18 DGF)
7th day
(𝑛 = 40, 18 DGF)
DGF (𝑛 = 18) 7.5(6.0–11.7)
8.2
(6.5–9.3)
7.5
(5.9–8.5)
6.9
(6.1–8.0)
6.4
(5.3–8.9)
Non-DGF (𝑛 = 22) 7.8(5.1–9.4)
6.3
(4.6–7.9)
4.3
(2.8–6.1)
2.5
(1.6–3.2)
1.9
(1.4–2.4)
Urine NGAL (ng/mL)
Median, (IQR)
3 to 6 h after surgery
(𝑛 = 30, 13 DGF)
1st day∗
(𝑛 = 35, 14 DGF)
2nd day
(𝑛 = 35, 15 DGF)
4th day
(𝑛 = 36, 15 DGF)
7th day
(𝑛 = 35, 16 DGF)
DGF (𝑛 = 18) 647(328–1648)
866
(500–1256)
834
(510–2632)
851
(549–1643)
407
(106–1249)
Non-DGF (𝑛 = 22) 256(105–446)
129
(64–306)
80
(29–138)
47
(36–91)
34
(26–57)
∗1st day = 8 to 12 h after surgery; values are medians and interquartile range (25th to 75th percentile).
Abbreviations: uNGAL: urinary neutrophil gelatinase associated lipocalin; IQR: interquartile range; DGF: delayed graft function; non-DGF: prompt function.
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Figure 1: Evolution of uNGAL levels through first week after
transplantation, according to graft function.Abbreviations: uNGAL:
urinary neutrophil gelatinase associated lipocalin; DGF: delayed
graft function.
Figure 2 shows the predicted uNGAL trajectories over time
for four hypothetical subjects: two recipients who developed
DGF (one with 4 years of dialysis and one with 10 years), and
two other patients with prompt graft function (similar time
on dialysis, 4 and 10 years). Hypothetically, the remaining
variables were equal in all four patients. The predicted
uNGALvalueswere estimated using the coefficients estimates
of Table 3 (e.g., the predicted uNGAL values at the first day
for a recipient with 4 years of dialysis with prompt function =
exp [(5.46 − 2.14) + 0.94 + 0.4 + (0.076 ∗ 4 years of dialysis)]
= 158 ng/mL).
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Figure 2: Predicted uNGAL values over time of four hypothetical
subjects, estimated from multiple linear mixed model presented
in Table 3. Abbreviations: uNGAL: urinary neutrophil gelatinase
associated lipocalin;DGF: delayed graft function; non-DGF: prompt
graft function.
3.3. Prediction of DGF by uNGAL Levels (ROC analy-
sis). Receiver-operating characteristic (ROC) curves showed
uNGAL on the first postoperative days were accurate in
predicting DGF (Tables 4 and 5). Table 4 displays the derived
sensitivities, specificities, and predictive values for uNGAL
at the cutoff concentrations that provided the maximum
sum of sensitivity and specificity. Regarding the areas under
the ROC curves (AUC), the ability of uNGAL to predict
DGF was moderately accurate at baseline and first day, and
highly accurate at second, fourth, and seventh days (Table 5,
Figure 3). In the first two posttransplant days the diagnostic
performance of uNGAL was better than of serum creatinine,
and quite similar to that of cystatin C.The reduction in serum
creatinine between first and second days resulted in AUC
= 0.78 [0.64–0.92] and was worse than uNGAL for DGF
prediction.
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Table 3: Results of the final linear mixed model for dependent variable ln(uNGAL) (𝑛 = 171 observations derived from 40 patients).
Coefficient estimate P value 95% CI
Intercept 5.46 <0.001 4.94 5.98
Graft function
DGF = 0 (prompt graft function) −2.04 <0.001 −2.64 −1.44
DGF = 1 (with DGF-reference) 0 — — —
Time
Time (3 to 6 h after surgery) 0.47 0.088 −0.07 1.00
Time (1st day) 0.94 0.001 0.41 1.47
Time (2nd day) 1.01 <0.001 0.49 1.53
Time (4th day) 1.02 <0.001 0.50 1.54
Time (7th day-reference) 0 — — —
Time∗DGF
Time (3 to 6 h after surgery)∗DGF = 0 1.40 <0.001 0.68 2.13
Time (1st day)∗ DGF = 0 0.40 0.257 −0.29 1.10
Time (2nd day)∗ DGF = 0 −0.37 0.295 −1.06 0.32
Time (4th day)∗DGF = 0 −0.73 0.039 −1.42 −0.03
Time (7th day)∗DGF = 0 (reference) 0 — — —
Time on dialysis 0.076 0.003 0.03 0.12
Abbreviations: uNGAL: urinary neutrophil gelatinase associated lipocalin; ln: natural logarithm; DGF: delayed graft function (DGF = 0, no delayed graft
function).
Table 4: Sensitivity, specificity, and predictive values for DGF using specific uNGAL cut-off values.
Time after transplant uNGAL cutoff (ng/mL) Sensitivity (%) Specificity (%) PPV NPV
Shortly after surgery (3 to 6 h) 479 77 88 87 79
1st day (8 to 12 h after surgery) 286 100 76 81 100
2nd day 277 93 90 90 93
4th day 232 93 95 95 93
7th day 63 94 84 86 93
DGF: delayed graft function; uNGAL: urinary neutrophil gelatinase-associated lipocalin; PPV: positive predictive value; NPV: negative predictive value.
3.4. Independent Association of uNGAL Levels and DGF
(Multivariable Analyses). Multivariable logistic regression
analyses revealed that uNGAL levels remained independently
associated with DGF at most time points, after adjusting for
clinically relevant risk factors for DGF (Table 6). Further-
more, recipient age was the other significant independent
predictor of DGF in almost all models. To be more clinically
relevant, estimates of DGF risk were converted to every
50 ng/mL of increase in uNGAL or per each 5 years of
increase in age, instead of estimates per each unit of increase.
3.5. Within One-Year after Kidney Transplantation. During
the first year, 10 KTx recipients were rehospitalized account-
ing for a total of 19 hospital admissions. There was one
rehospitalization in six patients, two in two patients, three
in one patient, and six rehospitalizations in one patient
with a psychological disorder and suicidal ideation. The
causes of rehospitalization were infection in five admissions
(mostly, urinary tract infection), renal dysfunction in six, and
nonrenal causes in the remaining eight admissions (suicidal
ideation, acute pulmonary edema, and neutropenia).
Excluding the recipient with several rehospitalizations
due to psychological decompensation, the length of hospital
stay of the remaining recipients admissions was 7 [3] days,
and no significant differences were found between recipients
from living or deceased donors.
The acute rejection episodes were collected throughout
the first posttransplant year. Ten recipients (25%) had an
acute rejection episode during inpatient hospitalization for
transplant surgery, and only one patient was rehospitalized
one month after KTx with an acute rejection episode con-
firmed by biopsy.
At one year after transplantation, all patients were alive
but two grafts were lost. At this time, the median plasma
creatinine was significantly higher in DGF group compared
to non-DGF: 1.6mg/dL [IQR: 1.2–2.5] versus 1.3mg/dL [IQR:
1.0–1.5], 𝑃 = 0.049.
3.6. Prognostic Value of First-Week uNGAL Levels in One-Year
Graft Function. Thecorrelation between uNGAL collected in
the first week after KTx and serum creatinine at one year
was explored. Except for uNGAL collected within the first
24 h after transplantation, uNGAL levels were positively cor-
related with serum creatinine evaluated at time of discharge,
and also at 1, 3, 6, and 12 months. Likewise, uNGAL levels at
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Table 5: Area under the receiver-operating characteristic curve at
each time point for uNGAL, serum creatinine, and serum cystatin
C for predicting DGF.
Time after
transplant AUC (95% CI) 𝑃 value
Urine NGAL
(ng/mL)
Shortly after
surgery (3 to 6 h) 0.77 (0.58–0.97) 0.010
1st day (8 to 12 h
after surgery) 0.88 (0.77–1.0) <0.001
2nd day 0.96 (0.90–1.0) <0.001
4th day 0.99 (0.97–1.0) <0.001
7th day 0.93 (0.86–1.0) <0.001
Serum
creatinine
(mg/dL)
Prior
transplantation 0.56 (0.38–0.74) 0.514
1st day (8 to 12 h
after surgery) 0.77 (0.61–0.93) 0.007
2nd day 0.90 (0.79–1.0) <0.001
4th day 0.95 (0.87–1.0) <0.001
7th day 0.93 (0.81–1.0) <0.001
Serum
cystatin C
(mg/L)
1st day (6 to 12 h
after surgery) 0.90 (0.79–1.0) <0.001
2nd day 0.96 (0.88–1.0) <0.001
4th day 0.95 (0.89–1.0) <0.001
7th day 0.93 (0.83–1.0) <0.001
DGF: delayed graft function; uNGAL: urinary neutrophil gelatinase-
associated lipocalin.
days 2, 4, and 7 were inversely correlated with eGFR at 6 and
12months (data not shown).
Theprognostic value of early uNGALvalues on long-term
allograft function (one year after KTx) was tested by mul-
tivariable analysis. In multivariable linear regression models
for serum creatinine at 12months, uNGAL measured on the
fourth and seventh days were independently associated with
one-year graft function, adjusting for established variables
that usually affect graft function, including acute rejection
episodes and rehospitalizations that occurred during the first
posttransplant year (Table 7).
4. Discussion
Themajor finding of this study is that uNGAL is a promising
biomarker for allograft dysfunction that can be easily and
noninvasively assayed in the early posttransplant period. We
prospectively evaluated uNGAL in a cohort of 40 kidney
allograft recipients during the first posttransplant week. At all
measured timepoints, uNGAL levelswere consistently higher
in patients who developed DGF, including the earliest levels
obtained from the first urine sample collected approximately
3 to 6 h after transplant surgery. At this time, clinical diagnosis
of DGF is yet not possible, but a simple and noninvasive
test can already recognize kidney dysfunction and stratify
patients according to likelihood of requiring posttransplant
dialysis.
It would be ideal to diagnose graft dysfunction with an
early and highly sensitive biologic marker of renal tubular
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Figure 3: Receiver-operating characteristic curves for uNGAL,
serum creatinine and changes in serum creatinine, and serum
cystatin C measured at posttransplant days 1 and 2 for predicting
delayed graft function. Abbreviations: uNGAL: urinary neutrophil
gelatinase associated lipocalin; Creat: serum creatinine; Cyst: serum
CystatinC;Creat2-Creat1: creatinine reduction rate between the first
and the second day.
injury. One of the most promising markers is NGAL, and our
findings provide further information for the use of uNGAL as
a diagnostic and prognostic tool for DGF. According to our
estimation, uNGAL values shortly after transplant surgery
will be much higher in patients who went on to develop
DGF and will rise further in the following days. In contrast,
patients with prompt function will have lower levels, which
decrease consistently along the week.The kinetics of changes
in these recipients compared to those who presented DGF is
quite different. It seems that, not only the baseline levels, but
also the pattern of uNGAL longitudinal changes can reflect
graft dysfunction.
The association between higher NGAL levels and DGF
after KTx has been previously published [16, 20, 22, 24, 25].
But the findings are not consistent regarding the kinetics of
uNGAL according to DGF. Hollmen et al. [22] found initial
levels of uNGAL higher inDGF patients, but on the following
day a decrease was observed, as it happened with recipients
with prompt function. As mentioned before, our study
did not confirm this declining in DGF patients. Recipients
who went on to develop DGF had initial higher levels of
uNGAL that rise further on the following posttransplant
days, differing from patients with prompt graft function.
Our findings are in agreement with results reported by Hall
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Table 6: Association of uNGAL with delayed graft function by multivariable analysis (logistic regression).
Delayed graft function
OR adjusted∗ 𝑃 value 95% CI
Model 1 (uNGAL at 3 to 8 h after surgery)
uNGAL0 (per 50 ng/mL of increase) 1.15 0.044 1.01–1.31
Recipient age (per 5 years of increase) 1.49 0.054 0.99–2.24
Model 2 with (uNGAL at day 1)
uNGAL1 (per each 50 ng/mL of increase) 1.22 0.012 1.05–1.42
Recipient age (per 5 years of increase) 1.99 0.022 1.11–3.57
Model 3 (uNGAL at day 2)
uNGAL2 (per each 50 ng/mL of increase) 1.35 0.004 1.10–1.66
Model 4 (uNGAL at day 4)
uNGAL4 (1 ng/mL increase) 3.01 0.035 1.08–8.40
Model 5 (uNGAL at day 7)
uNGAL7 (per each 50 ng/mL of increase) 1.43 0.050 1.01–2.04
Recipient age (per 5 years of increase) 1.73 0.038 1.03–2.90
Note: results given by logistic regression (backward Wald test).
Abbreviations: OR: odds ratio; 95% CI (95% confidence interval); uNGAL: urinary neutrophil gelatinase-associated lipocalin.
∗Adjusted for pretransplant time on dialysis, recipient gender and age, and donor age.
Table 7: Significant factors associated with serum creatinine at one year after kidney transplantation.
Regression coefficient adjusted∗ 𝑃-value 95% CI
Model with uNGAL at day 4
Donor gender (male versus female) 0.042 0.004 0.015–0.069
Donor age (years) 0.011 0.008 0.003–0.020
uNGAL4 (ln, ng/mL) 0.067 0.045 0.002–0.132
Model with uNGAL at day 7
Time on dialysis (ln, ng/mL) 0.042 0.004 0.015–0.069
Donor age (years) 0.018 0.002 0.008–0.029
uNGAL7 (ln, ng/mL) 0.138 0.007 0.041–0.235
Note: results given by multiple linear regression; serum creatinine (ln) at 12 months as the dependent variable. Only the significant variables associated with
serum creatinine are displayed. Abbreviations: uNGAL: urinary neutrophil gelatinase-associated lipocalin.
∗Adjusted for donor status, donor age, recipient age and gender, pretransplant time on dialysis, rehospitalizations, and acute rejection episodes throughout the
first year.
et al. [24]. It seems that, above and beyond the markedly
higher levels of uNGAL in patients with graft dysfunction,
the contrasting pattern of uNGAL longitudinal changes can
distinguish recipients who will need dialysis in the first week
posttransplantation.
To the best of our knowledge, this is the first report
that used linear mixed analysis in describing longitudinal
changes of uNGAL in the first week following KTx. Multiple
observations of a variable on a particular patient are likely
to be positively correlated, so they should not be treated as
independent measurements. Although models that take this
design into consideration are more complicated, they are also
more specific and powerful since they permit the study of
changes over time. Linear mixed analysis not only permits
to model individual changes over time, but also is able to
distinguish within-subject from between-subject sources of
variation [31].
In accordance with previously published data [16, 20–
22, 24], we confirmed the good performance of NGAL in pre-
dicting graft dysfunction in the early posttransplant period.
Using ROC analysis, our study also corroborates uNGAL
as a good diagnostic marker on identifying patients with
graft dysfunction and who subsequently required dialysis.
TheAUC-ROC for uNGALwasmoderately accurate forDGF
prediction within the first day after transplant, and it was
excellent at day 2 and day 4. We also determined the paired
sensitivity and specificity for the cutoff value of uNGAL,
calculated to be closest to the left upper corner of the ROC
space to predict DGF. At 8 to 12 h after surgery, a cutoff of
286 ng/mL had 100% sensitivity and 76% specificity for the
identification of DGF. Within the second day, uNGAL levels
higher than 277 ng/mL predicted DGF with a sensitivity
of 93% and specificity of 90%. Other studies showed also
impressive results. Parikh et al. [16] in a study that included 53
patients undergoing KTx, measured NGAL in urine samples
collected within the first 24 h following transplantation and
reported an AUC-ROC of 0.9, similar to ours obtained 8
to 12 h after surgery. Another study [24] conducted in 91
recipients evaluated uNGAL within 6 h after transplantation
and predicted subsequent DGF with an AUC-ROC = 0.81.
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Most recently, Hollmen et al. [22] undertook a large cohort
study that included 176 KTx recipients. Urine was collected
before transplant, at then at days 1, 3, 7, and 14, and uNGAL
was measured at each time point. The authors found and
AUC-ROC = 0.74 at day 1.
We report a superior performance of uNGAL level for
predicting DGF over serum creatinine measured at the same
time. UrinaryNGALmeasured at the first day predictedDGF
with an AUC-ROC of 0.93, which is markedly better than an
AUC-ROC = 0.76 shown by serum creatinine measured in
the same day, and also than an AUC-ROC = 0.83 obtained
from creatinine reduction ratio from first to second day,
but quite similar to cystatin C (0.95), a marker considered
more accurately to detect changes in renal function [32–
35]. Furthermore, our analyses also revealed that uNGAL
levels predicted DGF, even after adjusting for pretransplant
variables known to be traditionally associated with DGF.
Besides DGF, the other factors that significantly influ-
enced uNGAL levels were previous time on dialysis, recip-
ient’s age at time of transplantation and cold ischemia
time. These three variables were positively correlated with
uNGAL values. Mishra and coworkers [17] have shown
that the immunohistochemical staining intensity for NGAL
was strongly correlated with cold ischemia time and NGAL
expression was significantly increased in deceased donor
biopsies. We found that uNGAL levels were higher in graft
recipients fromdeceased donors, but only significantly higher
at the second day. It is known that prolonged cold preserva-
tion of kidneys can lead to severe injury, which is critical in
the success of deceased-donor kidney transplantation [36].
However, there is a progressive effort of our transplant team
to avoid prolonged cold preservation. Maybe this attempt
attenuated the effect of cold ischemic injury in kidneys
from deceased donors, which become comparable to living
donors concerning uNGAL values. An interesting finding
of our study was that uNGAL levels at all-time points were
correlated with length of hospital stay. It is well known
that the occurrence of DGF prolongs the recipient’s hospital
stay. And it is worthy of note to realize that patients with
early higher levels of uNGAL will expect longer time of
hospitalization, probably due to graft dysfunction.
As other studies [16–19, 24, 26, 37], we confirmed that
uNGAL levels were inversely correlated with eGFR and
positively correlated with serum creatinine at each measured
time point. We also showed that not only in the first week,
but longer after that, uNGAL levels measured in the first
seven days after KTx were still predictive of graft function
throughout the first year after transplantation. Even after
adjusting for donor status, acute rejection episodes, hos-
pitalizations occurred in the first year, and other known
variables that usually affect graft function, uNGAL evaluated
at days four and seven were predictive of one-year serum
creatinine, which can be considered a surrogate marker of
long-term graft survival [38, 39]. In contrast, Hollmen and
coworkers study [22] did not find any correlation between
uNGAL and renal function at one year. In their study, uNGAL
collected in the first two weeks after transplantation was only
correlated with renal function up to 3months. Our results do
not corroborate this lack of correlation and are in agreement
with a recent study that also associated perioperative uNGAL
levels to one-year allograft function [28].
Our study has several strengths. First, it is a prospective-
cohort design study. Second, we measured uNGAL at several
time points within the first posttransplant week, and not at
one single point. Longitudinal studies have the advantage of
providing detailed information about how a marker changes
over time; however the studies present some statistical com-
plexities, since the customary assumption that all observa-
tions are independent usually does not hold. And this was the
third strength of our study: the use of longitudinal methods
to handle the serial changes of uNGAL. A fourth strength was
the technical determination that we have chosen to measure
NGAL. We used a commercially available kit for uNGAL
determination (Abbott Architect NGAL), which is simple to
implement in routine practice and it is considered one of the
best methods for detecting acute kidney injury [40].
Similarly to other authors [16, 22], we have chosen to
measure NGAL in urine, instead of blood, since uNGAL
represents tubule damage in the kidney rather than filtration
from blood [14, 41]. An increased level of NGAL in urine
usually indicates injury of proximal tubular cells and seems
to be more specific compared to serum NGAL, which can be
produced by other organs and released into the circulation
following a transplant surgery [42]. Other advantages of
urinary diagnostics include the noninvasive nature of sample
collection and the reduced number of interfering protein
[43]. However, despite the undoubtedly value of urinary
markers of kidney injury, their use in transplant recipients
can be also a drawback because of possible transient graft
anuria, which may preclude the availability of urine and
consequently the lack of sample to measure NGAL. Due
to the shortcoming of urine biomarkers in anuric KTx
recipients, some studies have evaluated the performance of
serum/plasma NGAL in predicting graft function recovery
after KTx [21, 27]. As we did not measure serum/plasma
NGAL values, we could not compare their effectiveness in
predicting DGF in our sample. In our study, 4 or 5 recipients
were anuric in each measurement, resulting in 12% of our
patients not having urine sample to determine uNGAL in that
particular time point. The measurement of serum/plasma
NGAL could have been a valuable alternative in these
recipients, since it could also be obtained noninvasively in
patients who required dialysis during the transient period of
anuria.
Similar to other areas in medicine, in kidney transplan-
tation early diagnosis and timely intervention will improve
outcomes. Ischemic injury of the renal allograft is a critical
early insult that increases the risk of acute tubular necrosis
and long-term graft loss. If DGF could be detected in
the early hours after surgical procedure, maybe a tailored
and more individualized intervention could be achieved.
Perioperative fluid management must ensure the restoration
and maintenance of the intravascular volume, in order to
obtain an appropriate graft function. Aggressive hydration
has been recognized to be effective in avoiding DGF, but
fluid overload may also precipice the need of dialysis with
the risk of hipovolemia and consequent renal ischemia.
Early identification of DGF patients could allow to be more
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judicious and to modify postoperative fluid management
in favor of maintaining just adequate filling pressures to
maintain adequate intravascular volume and prevent fluid
overload [44]. Regarding immunosuppression, the induction
protocol chosen for this group of patients should have the
associated effect of decreasing DGF rates, by suppressing
leukocyte-rich vascular congestion and endothelial injury,
and the introduction of calcineurin inhibitors could be
avoided or delayed due to their vasoconstrictive properties.
Cytomegalovirus (CMV) infection has also direct and indi-
rect effects on transplant graft function, and some previous
evidence has been published relating the association between
the use of ganciclovir and the lower occurrence of DGF
[45]. Nowadays, the prophylaxis with valganciclovir should
be other aspect taken into account in recipients that we know
they will develop DGF, since this prophylaxis may do more
than just delay the occurrence of CMV disease.
Several studies were done in renal transplantation to
identify early biomarkers for the diagnosis of DGF. However,
there is still no routine application of any of these markers
in clinical transplantation. The present study clearly support
that uNGAL represents an early marker of graft injury and
is strongly associated with dialysis-based diagnosis of DGF
and one-year graft function. Other studies are necessary to
clarify the genesis and sources of plasma and urinary NGAL
and validate the accuracy of uNGAL as a diagnosticmarker of
renal graft injury and predictor for DGF in assorted centres,
across different practices and sets of variables.
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